First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008668 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Martin Wermke und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention Research Institute of Texas for co-funding.
Abstract (Originalsprache)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors. Trial design The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8 + T cells expressing a T cell receptor (TCR), which is specific for a nine amino acid peptide derived from MAGEA1. Eligible patients underwent leukapheresis, T cells were isolated, transduced with lentiviral vector carrying MAGEA1-specific TCR and following lymphodepletion (fludarabine/cyclophosphamide), infused with a median of 1.4×10 9 specific T cells (range, 0.086×10 9 –2.57×10 9 ) followed by interleukin 2. Safety of IMA202 No DLT was observed. The most common grade 3–4 adverse events were cytopenias, that is, neutropenia (81.3%), lymphopenia (75.0%), anemia (50.0%), thrombocytopenia (50.0%) and leukopenia (25.0%). 13 patients experienced cytokine release syndrome, including one grade 3 event. Immune effector cell-associated neurotoxicity syndrome was observed in two patients and was grade 1 in both. Efficacy of IMA202 Of the 16 patients dosed, 11 (68.8%) patients had stable disease (SD) as their best overall response (Response Evaluation Criteria in Solid Tumors V.1.1). Five patients had initial tumor shrinkage in target lesions and one patient with SD experienced continued shrinkage in target lesions for 3 months in total but had to be classified as progressive disease due to progressive non-target lesions. IMA202 T cells were persistent in peripheral blood for several weeks to months and were also detectable in tumor tissue. Peak persistence was higher in patients who received higher doses. Conclusion In conclusion, IMA202 had a manageable safety profile, and it was associated with biological and potential clinical activity of MAGEA1-targeting genetically engineered TCR-T cells in a poor prognosis, multi-indication solid tumor cohort. Trial registration numbers NCT04639245 , NCT05430555 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.
- National Center for Tumor Diseases, Dresden, Germany.
- Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.
- Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA.
- Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Jason John Luke, Andreas Acs, Apostolia M Tsimberidou
Förderung
- NCI NIH HHS
- Cancer Prevention Research Institute of Texas for co-funding
Zitieren
APA
Wermke, M., Holderried, T. A. W., Luke, J. J., Morris, V. K., Alsdorf, W. H., Wetzko, K., Andersson, B. S., Wistuba, I. I., Parra, E. R., Hossain, M. B., Grund-Gröschke, S., Aslan, K., Satelli, A., Marisetty, A., Satam, S., Kalra, M., Hukelmann, J., Kursunel, M. A., Pozo, K., …, & Britten, C. M. (2024). First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008668
Vancouver
Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008668
BibTeX
@article{Wermke2024,
author = {Wermke, Martin and Holderried, Tobias A W and Luke, Jason John and Morris, Van K and Alsdorf, Winfried H and Wetzko, Katrin and Andersson, Borje S and Wistuba, Ignacio I and Parra, Edwin R and Hossain, Mohammad B and Grund-Gröschke, Sandra and Aslan, Katrin and Satelli, Arun and Marisetty, Anantha and Satam, Swapna and Kalra, Mamta and Hukelmann, Jens and Kursunel, M Alper and Pozo, Karine and Acs, Andreas and Backert, Linus and Baumeister, Melissa and Bunk, Sebastian and Wagner, Claudia and Schoor, Oliver and Mohamed, Ali S and Mayer-Mokler, Andrea and Hilf, Norbert and Krishna, Delfi and Walter, Steffen and Tsimberidou, Apostolia M and Britten, Cedrik M},
title = {First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008668}
}
EUVIMED